Contrasting of Celgene Corporation (CELG) and Wave Life Sciences Ltd. (NASDAQ:WVE)

As Biotechnology businesses, Celgene Corporation (NASDAQ:CELG) and Wave Life Sciences Ltd. (NASDAQ:WVE), are affected by contrast. This especially applies to their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celgene Corporation 15.28B 4.12 4.05B 5.57 12.34
Wave Life Sciences Ltd. 11.70M 104.64 139.61M -4.86 0.00

Table 1 highlights Celgene Corporation and Wave Life Sciences Ltd.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
Celgene Corporation 26.51% 56.8% 8.7%
Wave Life Sciences Ltd. -1,193.25% -112.2% -55%

Liquidity

Celgene Corporation’s Current Ratio and Quick Ratio are 2.1 and 2 respectively. The Current Ratio and Quick Ratio of its competitor Wave Life Sciences Ltd. are 1.9 and 1.9 respectively. Celgene Corporation therefore has a better chance of paying off short and long-term obligations compared to Wave Life Sciences Ltd.

Analyst Recommendations

The Recommendations and Ratings for Celgene Corporation and Wave Life Sciences Ltd. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Celgene Corporation 0 6 2 2.25
Wave Life Sciences Ltd. 0 0 0 0.00

The consensus target price of Celgene Corporation is $88.17, with potential downside of -2.00%.

Insider and Institutional Ownership

The shares of both Celgene Corporation and Wave Life Sciences Ltd. are owned by institutional investors at 76.3% and 82.3% respectively. Insiders owned 0.33% of Celgene Corporation shares. Competitively, Wave Life Sciences Ltd. has 0.4% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Celgene Corporation -4.9% -8.98% -22.96% -12.32% -33.15% -34.19%
Wave Life Sciences Ltd. 1.07% 6.8% -7.8% -0.19% 32.31% 37.78%

For the past year Celgene Corporation has -34.19% weaker performance while Wave Life Sciences Ltd. has 37.78% stronger performance.

Summary

Celgene Corporation beats Wave Life Sciences Ltd. on 10 of the 12 factors.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

WAVE Life Sciences Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in HuntingtonÂ’s disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In HuntingtonÂ’s disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company has a research, license, and option agreement with Pfizer Inc. for the discovery, development, and commercialization of stereopure oligonucleotide therapeutics; and research collaboration with nLife Therapeutics S.L. exploring cell-specific targeting of nucleic-acid therapeutics in the central nervous system. WAVE Life Sciences Ltd. was founded in 2012 and is based in Cambridge, Massachusetts.